Ascletis reports preclinical results for obesity drug candidates
Ascletis has released findings from preclinical studies on two new obesity treatment candidates during the 2026 ObesityWeek conference.

Ascletis presented preclinical data on two obesity-focused drug programs at the ObesityWeek 2026 conference. The company reported that ASC30_48, an oral dual fixed-dose combination targeting GLP-1R and GIPR receptors, demonstrated a 52 percent relative improvement in weight loss compared to ASC30 monotherapy in preclinical models.
The firm also detailed progress on ASC37, a triple peptide agonist targeting GLP-1R, GIPR, and GCGR. This candidate is engineered for extended-release delivery, with the goal of being administered once monthly or once quarterly. This design strategy aims to address the limitations of existing weekly injectable therapies by increasing potential patient adherence.
The global obesity drug market remains highly competitive, with multiple pharmaceutical firms racing to develop more convenient and potent therapies. Ascletis's focus on both oral delivery and long-acting injections reflects broader industry efforts to move beyond first-generation GLP-1 treatments. The candidates remain in the preclinical stage as the company evaluates potential paths for clinical progression.